Artrya (ASX: AYA) has signed a commercial agreement with US-based Northeast Georgia Health System (NGHS) for the use of its Salix AI cloud platform for point-of-care assessment and management of coronary artery disease.
The deal will licence Salix as a software-as-a-service platform with a fixed monthly subscription fee over a 36-month term and a minimum value of US$300,000.
The Salix coronary plaque and coronary flow modules on clearance by the US Food and Drug Administration will generate additional fee-per-scan revenue.
Cardiology Network Usage
NGHS will introduce the platform to its network of five hospitals, outpatient centres, and physician practices within the Georgia Heart Institute cardiology group for use in the routine care of patients with suspected or confirmed coronary artery disease who are undergoing CT angiography.
Artrya’s Atlanta-based team will offer onboarding and training, clinician engagement, and comprehensive technical support to NGHS staff during the roll-out period, helping assist in the management of more than 100,000 patients each year.
The company expects the Salix platform to seamlessly interact with the picture archiving and communication system and electronic medical record technologies currently used in medical practice.
Second Commercial US Order
Artrya chief executive officer John Konstantopoulos said the NGHS agreement represented the company’s second US commercial order, and would accelerate its regional expansion strategy.
“We remain on track to convert all three of our US foundation partners to commercial customers this year and our new Customer Success team is already playing a leading role in the integration and support of our technology,” he said.
Georgia Heart Institute chief cardiology officer Dr Mudassar Ahmed said the integration of Salix into the workflow would help streamline interpretation, reduce variability, and deliver actionable insights for patients, offering faster, more accurate diagnoses and improved outcomes.
“Through our work [with Artrya] during the past two years, we have seen that Salix can bring a new dimension to our practice by supporting earlier identification of risk and enabling more proactive treatment strategies,” he said.
“This latest AI-enabled technology reflects our commitment to advancing cardiovascular medicine and ensures patients across Georgia Heart Institute can benefit from faster, more accurate diagnoses and improved outcomes,” medical director Dr Zaid Said added.
